Adamis Receives FDA Approval For ZIMHI
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. ZIMHI is a
Adamis Stock Jumps As Its Oral COVID-19 Drug Trial Starts Dosing
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has initiated dosing in the Phase 2/3 trial for Tempol, an oral antiviral product candidate, in adult…
Immunology Journal Publishes Data For Adamis’ COVID-19 Candidate
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has announced Tempol data publication in the peer-reviewed journal Clinical Immunology. Tempol is a novel antioxidant that…
Adamis Pharmaceuticals Highlights Publication With The Human Immune Monitoring Center At Stanford Demonstrating Tempol ‘Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells’
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced a publication in the peer reviewed journal, Clinical Immunology, entitled "Tempol, a novel antioxidant, inhibits both activated T cell and
Mid-Day Market Update: Macy’s Jumps After Q2 Results; PharmaCyte Biotech Shares Drop
Midway through trading Thursday, the Dow traded down 0.40% to 34,819.43 while the NASDAQ rose 0.07% to 14,535.52. The S&P also fell, dropping 0.03% to 4,398.74.